The 5 most cited ENT studies examined inhibition of ROS scavengers in cancer stem cells with buthionine sulfoximine, nimorazole, EGFR inhibitors, cisplatin, and beta - 1 Integrin inhibitors. Here, EGFR is linked to cancer.